Medha D Joshi, Ph.D.

Chair, Pharmaceutical Sciences
Glendale, AZ

Home / Academics / Our Faculty / Medha D Joshi, Ph.D.


Dr. Medha D Joshi is an Associate Professor in Pharmaceutical Sciences at Midwestern University’s Chicago College of Pharmacy. Dr Joshi has expertise in lipid based drug delivery systems including solid lipid nanoparticles (SLN), micro emulsions, self emulsifying drug delivery systems (SMEDDs), nanosuspensions, and liposomes, targeted drug delivery etc. Her research program at Midwestern university is focused on application of nanoparticulate targeted delivery a) to neurogenetic peptides for their delivery to the blood brain barrier and b) reduction of maternal-fetal toxicity of drugs across the placental barrier. She has more than 30 peer reviewed research articles, 2 patents and 3 book chapters to her credit. She has been a Principle Investigator and co-investigator on several intramural and extramural grants such as Alzheimer’s Drug Discovery foundation, NIH AREA grant etc.

Chair, Pharmaceutical Sciences

Glendale, AZ

College of Graduate Studies - AZ
College of Pharmacy
Glendale Campus

Pharmaceutical Sciences


Send Me
a Message


Institute of Chemical Technology (UDCT)
India | 2007 | Ph.D.
Pune University
India | 2002 | M.S.
Pune University
India | 2000 | B.Pharm.

Courses Taught

  • PSCIG 1540: Phamaceutical Calculations
  • PSCIG 1541: Phamaceutics-I


1.     Design and development of a clinically acceptable, long circulating liposomal delivery system for IRL-1620 and its evaluation in cerebral ischemia rat models.

In the present study, we propose to test the hypothesis that polyethylene glycol (PEG)ylated liposomal delivery of ETB receptor agonist, IRL-1620 may be efficacious in the treatment of cerebral ischemia. PEGylated liposomes encapsulating IRL-1620 with and without a cationic charge and "targeted" PEGylated liposomes to the transferrin receptor on the brain endothelium will be formulated. Further, these nanocarriers will be tested for their neuroprotection efficiency on pheochromocytoma cells in vitro. The liposomal nanocarriers of IRL-1620 will be elucidated for their ability to accumulate in the brain and amelioration of infarct volume, neurological deficit and motor functions in vivo, in a cerebral ischemia rat model. This study will help in generating the proof of concept that by delivering IRL-1620 in long circulating PEGylated liposomal nanocarriers, higher efficiency in dose and dosing frequency can be achieved. This will have a tremendous clinical significance in the management of stroke, wherein restoration of blood flow and attenuation of secondary damage to the penumbral area by IRL-1620 will be achieved for a longer period of time with fewer side effects and at a higher efficacy.

2. HPLC/LCMS assay development for analytical estimation  of actives from biological matrices

3. Classifying and overcoming fetal and maternal vancomycin-induced kidney injury: a pregnant rat model to understand and a new formulation to circumvent  

Approximately 90% of pregnant women and their fetuses are exposed to at least one medication during the pregnancy. The FDA previously classified the safety of medications in pregnancy as “A,B,C,D, or X” (X=teratogenic/avoid) according to their teratogenicity potentials; however, these classifications have been removed. Hence, clinicians are forced now more than ever to rely on primary medical literature for the safety of drugs during pregnancy. Vancomycin is a commonly used antibiotic during pregnancy for the treatment of severe sepsis and a candidate drug for our study. Although vancomycin was previously FDA classified as pregnancy category B, emerging data suggest kidney damage in adults. Further, data suggests that vancomycin crosses the placental barrier, though early toxicity studies have not employed the more sensitive assessments of kidney function necessary to classify damage, thus less is known about vancomycin’s toxicity to the fetus. Because of the common use and importance of vancomycin for life-threatening infections to the mother, vancomycin serves as a candidate drug for 1) improved understanding of the relationship between drug exposure and fetal kidney toxicity and 2) molecular modification to retain efficacy while circumventing toxicity to the mother and fetus.

AIM1: Quantify the relationship between fetal vancomycin exposure and kidney injury to rat pups

Details: Methodologies that were not previously studied, such as the analysis of Kidney Injury 1 molecule, are highly sensitive and specific for vancomycin kidney injury. Additionally, we will measure vancomycin concentrations in the rat pup kidneys to see if accumulation occurs. 

AIM2: Develop and characterize a liposomal formulation of vancomycin designed to minimize transplacental transfer

Details: The parent compound will be encapsulated in liposomal core in order to minimize transplacental crossing to the fetus and renal tubular transit for the mother, thereby circumventing injury for both fetus and mother.



  • Original Research Articles with impact factor (IF) of journal listed.
  1. Joshi MD. and Patravale V. (2006) Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib. Drug Development and Industrial Pharmacy 32:911-918 PubMed PMID: 16954103. IF= 3.727
  2. Shah K., Date A., Joshi MD., and Patravale V. (2007) Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. International Journal of Pharmaceutics 345:163-171 PubMed PMID: 20055085. IF=6.51
  3. Joshi MD., Pathak S, Sharma S and Patravale V (2008) Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. International Journal of Pharmaceutics 364:119-126 doi: 10.1016/j.ijpharm.2008.07.032. PubMed PMID: 18765274. IF=6.51
  4. Joshi MD., Pathak S, Sharma S and Patravale V (2008) Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria. International Journal of Pharmaceutics 362:172-178 doi: 10.1016/j.ijpharm.2008.06.012. PubMed PMID: 18611435. IF=6.51
  5. Joshi MD. and Patravale V (2008) Nanostructured lipid carrier (NLC) based gel of celecoxib. International Journal of Pharmaceutics 346:124-132 PubMed PMID: 17651933. IF=6.51
  6. Shah K, Joshi MD., and Patravale V (2009) Biocompatible microemulsions for fabrication of glyceryl monostearate solid lipid nanoparticles (SLN) of tretinoin. Journal of Biomedical Nanotechnology 5:396-400 doi: 10.1166/jbn.2009.1048. PMID: 20055085. IF=4.483
  7. Joshi MD., Unger W, van Beelen A, Bruijns S, Litjens M, van Bloois L, Kalay H, van Kooyk Y and Storm G (2011) DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations. International Journal of Pharmaceutics 416:426-432 doi: 10.1016/j.ijpharm.2011.02.055. PubMed PMID: 21371544. IF=6.51
  8. Patil S, Joshi MD., Pathak S, Sharma S and Patravale V (2012) Intravenous beta-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation. The Journal of antimicrobial chemotherapy 67:2713-2716 doi: 10.1093/jac/dks293. Epub 2012 Aug 16. PMID: 22899802. IF=5.758
  9. Unger W, van Beelen A, Bruijns S, Joshi MD., Fehres C, van Bloois L, Verstege M, Ambrosini M, Kalay H, Nazmi K, Bolscher J, Hooijberg E, de Gruij T, Storm G, and van Kooyk Y (2012) Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. Journal of controlled release 160:88-95 doi: 10.1016/j.jconrel.2012.02.007. PubMed PMID: 22366522. IF=11.467
  10. Jain S, Basu H, Prabhu P, Soni U, Joshi MD., Mathur, D, Patravale V, Pathak S and Sharma S (2014) Parasite Impairment by Targeting Plasmodium-Infected RBCs Using Glyceryl-dilaurate Nanostructured Lipid Carriers. Biomaterials 35: 6636-6645 doi: 10.1016/j.biomaterials.2014.04.058. PubMed PMID: 24818881. IF=15.304
  11. Kain V, Ingle K, Prabhu S, Serhan C., Joshi MD., and Halade G (2015) Resolvin D1 activates inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function, Journal of Molecular and Cellular Cardiology 84: 24-35, doi: 10.1016/j.yjmcc.2015.04.003. Epub 2015 Apr 11. PubMed PMID: 25870158; PubMed Central PMCID: PMC4468047. IF=5.763
  12. Joshi MD.*, Oesterling B., Wu C., Gwizdz N., Pais G., Briyal S., and Gulati A. (2016) Evaluation of liposomal nanocarriers loaded with ETB receptor agonist, IRL-1620, using cell-based assays, Neuroscience, 312, 141-152 doi: 10.1016/j.neuroscience.2015.11.016. PubMed PMID: 26592721. IF=3.708
  13. Joshi MD. *, Park G., Pichlik J., Patel K., and Patel R. (2017) In vitro evaluation of bortezomib encapsulated in cationic and C6-ceramide liposomes, Journal of Pharmaceutical Sciences and Pharmacology, 3, 1-9.
  14. Joshi MD., O’Donnell J. N., Venkatesan N., Chang J., Nguyen H, Rhodes N., Pais G., Chapman R., Griffin B., and Scheetz M, (2017) High-performance liquid chromatography (HPLC) method for rich pharmacokinetic sampling schemes in translational rat toxicity models with vancomycin, Clinical and Translational Science, open access, Nov;10(6):496-502. doi 10.1111/cts.12484 doi: 10.1111/cts.12484. Epub 2017 Jul 4. PubMed PMID: 28675684; PubMed Central PMCID: PMC5698807. IF= 4.516
  15. O'Donnell J., Rhodes N. J., Lodise T., Prozialeck W., Miglis C. M., Joshi MD., Natarajan V., Pais G., Cluff C., Lamar P., Briyal S., Zhan Z., Day J.Z., Gulati A., Scheetz M. H, (2017) 24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury Antimicrobial Agents and Chemotherapy. Oct 24;61(11). pii: e00416-17. doi: 10.1128/AAC.00416-17. Print 2017 Nov. PubMed PMID: 28807910; PubMed Central PMCID: PMC5655072. IF= 5.938
  16. O’Donnell J. N., Rhodes N. J., Miglis C., Catovic L., Liu J., Cluff C., Pais G., Avedissian S., Joshi MD., Griffin B., Prozialeck W., Gulati, A., Lodise T. P., Scheetz M. H. (2017) Doses, durations, and gender predict vancomycin-induced kidney injury in pre-clinical studies, International Journal of Antimicrobial Agents, pii: S0924-8579(17)30304-7. doi: 10.1016/j.ijantimicag.2017.08.012. PubMed PMID: 28803934. IF=15.441
  17. Schlich M.; Sinico C.; Valenti D.; Gulati A.; Joshi MD.; Meli V.; Murgias S., Xanthos T. (2019) Towards long-acting adrenaline for cardiopulmonary resuscitation: production and characterization of a liposomal formulation, International Journal of Pharmaceutics, 557, .105-111; PMID: 30586629 IF=6.51
  18. Avedissian S., Pais G.; Joshi MD.; Rhodes N.; Scheetz M., A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime mSphere (2019) 4 (1) e00595-18; DOI: 10.1128/mSphere.00595-18, PMID: 30700511, PubMed Central PMCID: PMC6354808. IF=4.17
  19. Avedissian S. N., Pais G., O’Donnell J. N., Lodise T. P., Liu J., Prozialeck W., Joshi MD., Lamar P., Becher L., Gulati A., Hope W., Scheetz M. H., (2019) Twenty-four-hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model, Journal of Antimicrobial Chemotherapy, 74(8):2326-2334. doi: 10.1093/jac/dkz167, PMID: 31065686 PMCID: PMC6640290. IF=5.758
  20. Joshi MD*, Pais GM, Chang J, Hlukhenka K, Avedissian SN, Gulati A, Prozialeck W, Lamar PC, Zhang Z, Scheetz MH, Griffin B. (2019) Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model. Antimicrobial Agents and Chemotherapy 63(10). pii: e00761-19. doi: 10.1128/AAC.00761-19, PMID: 31332061 PMCID: PMC6761542. IF=5.938
  21. Verdone M., Joshi MD, Bodenstine T. M., Green J., Lynch S., Gettig J. P., Fjortoft N., (2020) Impact of an Online, Self-Directed Pre-Pharmacy Bridging Course on Students’ Academic Performance, American Journal of Pharmaceutical Education, 84 (1), IF=2.047
  22. Avedissian SN, Pham M, Joshi MD, Scheetz MH, Salamatipour A, Panickar JM, Hlukhenka K., Miglis CM, Chalkias A, Xanthos T, Pharmacokinetic disposition of amiodarone when given with an intralipid rescue strategy (2021), Pharmaceutics, 13 (4), 539 IF=6.525
  23. Avedissian SN, Pais GM, Pham M, Liu J, Chang J, Hlukhenka K, Prozialeck W, Griffin B, Gulati A, Joshi MD, Mu Y, Scheetz MH. Vancomycin Pharmacokinetics in a Pregnancy Rat Model. Antimicrobial Agents and Chemotherapy (2022) May 17;66(5): e0005622. doi: 10.1128/aac.00056-22. Epub 2022 Apr 21. PMID: 35446134; PMCID: PMC9112916. IF=5.938
  24. Papp N., Panicker J., Rubino J., Pais G., Czechowicz A., Prozialeck W., Griffin B, Weissig V., Scheetz M., Joshi MD*, In Vitro Nephrotoxicity and Permeation of Vancomycin Loaded Liposomes, (2022), Published in special section: Drugs in Pregnancy and Lactation of Pharmaceutics 2022, 14, 1153. IF=6.525
  25. Date A, Joshi MD, and Patravale V (2007) Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Advanced Drug Delivery Reviews 59:505-521 PubMed PMID: 17574295. IF=17.873
  26. Joshi MD* and Muller R (2009) Lipid nanoparticles for parenteral delivery of actives. European Journal of Pharmaceutics and Biopharmaceutics 71:161-172 doi: 10.1016/j.ejpb.2008.09.003. PubMed PMID: 18824097. IF=5.589
  27. Joshi MD, Unger W, Storm G, van Kooyk Y and Mastrobattista E (2012) Targeting tumor antigens to dendritic cells using particulate carriers. Journal of controlled release 161:25-37 doi: 10.1016/j.jconrel.2012.05.010. PubMed PMID: 22580109. IF=11.467
  28. Prabhu P, Patravale V and Joshi MD* (2012) Nanocarriers for Effective Topical Delivery of Anti-Infectives. Current Nanoscience 8:491-503. IF=1.824
  29. Mehendale R, Joshi MD and Patravale VB (2013) Nanomedicines for treatment of viral diseases. Critical reviews in therapeutic drug carrier systems 30:1-49 PubMed PMID: 23510109.IF=4.889
  30. Oesterling B, Gulati A and Joshi MD* (2014) Nanocarrier Based Approaches for Treatment and Detection of Alzheimer's disease. Journal of Nanoscience and Nanotechnology 14:137-156 PubMed PMID: 24730256. IF=1.354
  31. Li W, Joshi MD, Singhania S, Ramsey K, Murthy A (2014) Peptide Vaccine: Progress and Challenges, published in the special issue: Peptide Vaccine, Vaccines 2, 515-536 doi: 10.3390/vaccines2030515.PubMed PMID: 26344743; PubMed Central PMCID: PMC4494216. IF=4.961
  32. Prabhu R, Patravale V and Joshi MD* (2015) Polymeric nanoparticles for targeted treatment in oncology: Current insights. International Journal of Nanomedicine, 10, 1001-1018 doi: 10.2147/IJN.S56932. Review. PubMed PMID: 25678788; PubMed Central PMCID: PMC4324541.IF= 7.033
  33. Joshi MD*, Klausner EA, (2022) Course design, delivery, and assessment strategies for pharmaceutical calculations course in a Doctor of Pharmacy program: A Review, Currents in Pharmacy Teaching and Learning, Volume 14 Issue 4, 526-535 IF=1.387
    • General Publications/editorials, letters, viewpoints
  34. Joshi MD and Patravale V (2003) Solid Lipid Nanoparticles: Potential in Drug Delivery, in Souvenir of 5th International symposium on innovations in pharmaceutical sciences and technology (arranged by BVPERD, Ahmadabad), Mumbai, India
  35. Joshi MD and Patravale V (2005) Nanocarriers for Diagnostic Applications, in Souvenir of 1st Indo-Japanese Conference Mumbai, India
  36. Joshi MD and Patravale V (2006) Future Nanotechnology in Pharma Industry, in Pharmabiz Mumbai, India.
  37. Joshi MD* (2013) Research highlights from the latest articles in Nanomedicine. Nanomedicine, Future Medicine 8:1-3.
  38. Joshi MD (2014) Interviewed for Volunteer spotlight section; Volunteering: a way to connect, build, and change in Controlled Release Society’s newsletter, Volume 31, No 6
  39. Joshi MD (2016) Interviewed for "Life Science Avenues and Opportunities" (LSAO), A complete guide to step up the life science career ladder in the Inspiring Role Models in the Life Sciences Sector.
  40. Joshi MD*, (2016) Nanomedicines for treatment of Stroke-Opinion Article, International Journal of Nanomedicine and Nanosurgery 2(3)
  41. Joshi MD*, (2017) CRS newsletter editorial: Boston: the city of champions.
  42. Joshi MD*, (2017) Drug delivery during pregnancy: how can nanomedicine be used? Therapeutic Delivery, 8(12), 1023-1025. doi: 10.4155/tde-2017-0084. PubMed PMID: 29125062.
  43. Joshi MD*., (2020) Novel teaching and assessment strategies for pharmaceutical calculations course: A review, Association of Pharmaceutical Teachers of India, Women's forum e-newsletter, Themed Education 4.0.*: corresponding author


  1. Member, American Association of Pharmaceutical Scientists (AAPS)
  2. Member, Controlled release Society (CRS)
  3. Member, American Nano Society, USA
  4. Member, American association of colleges of pharmacy (AACP)
  5. Member, Chicagoland Pharmaceutical Discussion Group
  6. Life Member, Indian Pharmaceutical Association (IPA), Mumbai, India
  7. Life Member, Indian Women Scientist Association, Mumbai, India


  1. Research faculty for NIH grant#5664 R15 2014-2017“Elucidation of an informed drug dose dosing scheme to minimize kidney injury” Marc Scheetz (PI) Medha Joshi (Research Faculty) 
  2. Co- investigator for a grant from the Alzheimer’s Drug Discovery foundation for a grant proposal "Nanocarrier formulation of ETB receptor agonist, IRL-1620, for the treatment of Alzheimer's disease" Anil Gulati (PI), Medha Joshi (Co-I) for the year 2012-2013. 
  3. Co- investigator for a grant from Care Foundation for $12,500 “Defining the Link between Cefepime Exposure and Effect in Canine Pneumonia: A Two-Way Bridge Serving Dogs and Humans” for Jan 2016-Dec 2017. Marc Scheetz (PI) Medha Joshi (Co-I) 


  1. MWU Chicago College of Pharmacy, PS-1 class teacher of the year 2017-2018 award by class of 2021, runner up 2017, 2019, 2020
  2. Scholarship conferred by Deutscher Akademischer Austausch Dienst (DAAD) i.e. German Academic Exchange Service to pursue Post doctoral research studies at Free University of Berlin
  3. Awarded best poster award for the presentation entitled ‘Hydrophobic nanostructured lipid carriers as novel modification for dermal application’ at European Workshop on Particulate Systems, Berlin, May 30-31, 2008
  4. Awarded best poster award for the presentation entitled ‘Nanoject: Nanostructured Lipid Nanocarrier based intravenous injection of Artemether’ at the 7th International Symposium on Advances in Technology and Business Potential of New Drug Delivery Systems, 13-14 February, 2007, Mumbai, India
  5. Mahindra Search for Talent Scholarship for standing first at the M. Pharmacy Examination, January 2002.
  6. Young scientist travel grant by Council of Scientific and Industrial Research (CSIR), Ministry of Human Resource and Development, Government of India to attend and present posters at 32nd Annual Meeting & Exposition of the Controlled Release Society, Miami Florida, USA, June 18-22, 2005
  7. Travel grant by Shalaks Pharmaceuticals, New Delhi to attend and present posters at 32nd Annual Meeting & Exposition of the Controlled Release Society, Miami Florida, USA, June 18-22, 2005.
  8. Two times University ranker 1st in Pune University at M. pharmacy level 2002 and 10th in Pune University at B. Pharmacy 2000.
  9. Biography appeared in Stanford who’s who and Marquis who’s who in the year 2011.
  10. PS-1 Teacher of the year awarded by class of 2021 at Midwestern University, Chicago College of Pharmacy
  11. 2020 AAPS Best Abstract Award, Abstract entitled “In Vitro Evaluation of Nephrotoxicity and Permeation Studies on Vancomycin Loaded Liposomes” was among the top 10% of abstracts based on high ratings by AAPS Abstract Screening Committee.